D.A. Davidson & CO. Sells 7,789 Shares of DexCom, Inc. (NASDAQ:DXCM)

D.A. Davidson & CO. reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 23.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,789 shares of the medical device company’s stock after selling 7,789 shares during the period. D.A. Davidson & CO.’s holdings in DexCom were worth $1,928,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in shares of DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after purchasing an additional 214,136 shares during the period. Jennison Associates LLC grew its stake in shares of DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares during the period. Groupama Asset Managment grew its stake in shares of DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after purchasing an additional 31,358 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after purchasing an additional 876,739 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of DexCom by 11.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 0.6 %

NASDAQ:DXCM opened at $88.78 on Friday. The stock’s fifty day moving average price is $83.50 and its two-hundred day moving average price is $76.06. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market cap of $34.69 billion, a price-to-earnings ratio of 62.08, a P/E/G ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,083 shares of company stock worth $3,309,794. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on DXCM. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Wells Fargo & Company boosted their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Citigroup boosted their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.